TP53 and neoplasm: In the case of RCCs, a recent meta-analysis confirmed that TP53-mutant tumors, manifesting the characteristic, subsequent, defective p53 transcript immunohistochemical overexpression, will also demonstrate more aggressive clinical and pathological tumor traits and will hold a much more unfavorable prognosis [77].